Drug Approval | February 17, 2026
FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma
Iberdomide has the potential to be the first approved CELMoD agent
Iberdomide has the potential to be the first approved CELMoD agent
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
